Matches in Wikidata for { <http://www.wikidata.org/entity/Q66064998> ?p ?o ?g. }
Showing items 1 to 44 of
44
with 100 items per page.
- Q66064998 description "assaig clínic" @default.
- Q66064998 description "clinical trial" @default.
- Q66064998 description "clinical trial" @default.
- Q66064998 description "clinical trial" @default.
- Q66064998 description "clinical trial" @default.
- Q66064998 description "ensaio clínico" @default.
- Q66064998 description "ensayo clínico" @default.
- Q66064998 description "ensayu clínicu" @default.
- Q66064998 description "essai clinique" @default.
- Q66064998 description "klinisch onderzoek" @default.
- Q66064998 description "клінічне випробування" @default.
- Q66064998 name "Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma" @default.
- Q66064998 name "Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma" @default.
- Q66064998 type Item @default.
- Q66064998 label "Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma" @default.
- Q66064998 label "Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma" @default.
- Q66064998 prefLabel "Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma" @default.
- Q66064998 prefLabel "Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma" @default.
- Q66064998 P1050 Q66064998-4A781F61-013E-40A4-8E8D-EB7233879AF5 @default.
- Q66064998 P1132 Q66064998-65C4213E-D1B7-4700-9FCA-B4DF1D144F1F @default.
- Q66064998 P1476 Q66064998-85EF5DB7-293F-40F4-BA9C-E0CC5E7DFEA6 @default.
- Q66064998 P17 Q66064998-1173CC57-0CD7-4F7D-B3FB-4EB2C7B8C338 @default.
- Q66064998 P2899 Q66064998-33F2BDA5-74F8-44E7-800B-C31653A92605 @default.
- Q66064998 P3098 Q66064998-B2BDB6C9-B9A7-42F7-B7E7-47E122A5CC19 @default.
- Q66064998 P31 Q66064998-0871EB75-E244-41A3-A130-86BD90E1E9B3 @default.
- Q66064998 P4844 Q66064998-0243E731-F55A-4F88-8801-E345CD63A9F5 @default.
- Q66064998 P4844 Q66064998-3C28D8B0-3732-4A1C-B44F-6600CF1E0E7C @default.
- Q66064998 P580 Q66064998-8ED70BFA-DAD8-4A55-A502-F6031319C210 @default.
- Q66064998 P582 Q66064998-C8DF465A-C0CC-4148-88D4-B9828009758F @default.
- Q66064998 P6099 Q66064998-BF09C59A-7E29-4E55-B85E-CB6C167248B3 @default.
- Q66064998 P8363 Q66064998-5EACBB64-793B-4AD3-9568-B0292EBAD015 @default.
- Q66064998 P1050 Q180614 @default.
- Q66064998 P1132 "+20" @default.
- Q66064998 P1476 "Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma: A Pilot Study" @default.
- Q66064998 P17 Q30 @default.
- Q66064998 P2899 "+18" @default.
- Q66064998 P3098 "NCT03972046" @default.
- Q66064998 P31 Q30612 @default.
- Q66064998 P4844 Q7679524 @default.
- Q66064998 P4844 Q7833138 @default.
- Q66064998 P580 "2019-06-24T00:00:00Z" @default.
- Q66064998 P582 "2021-06-24T00:00:00Z" @default.
- Q66064998 P6099 Q42824440 @default.
- Q66064998 P8363 Q78089383 @default.